FEB 22, 2019 – Treventis is pleased to announce that internationally recognized ALS researcher Dr. Janice Robertson has joined its Scientific Advisory Board. Dr. Robertson, a Canada Research Chair in Amyotrophic Lateral Sclerosis and a Ontario Premier Research Excellence awardee, is Professor at the Tanz Centre for Research in Neurodegenerative Diseases and of the Department […]

Dr. Sultan Darvesh, neurologist, medicinal chemist, and Treventis founder was as an invited lecturer to the 58th annual Canadian Association of Neuropathogists (CANP), held in Halifax, Nova Scotia on October 4, 2018.  Dr. Darvesh delivered a lecture entitled “Butyrylcholinesterase as a Biomarker for Alzheimer’s Disease” in which he explained the neuropathology of butyrylcholinesterase. He also […]

Treventis founder Dr. Sultan Darvesh was elected a Fellow of the Canadian Academy of Health Sciences at an induction ceremony on Sep 13, 2018, in Vancouver, British Columbia.  The citation for this prestigious honor reads: “Induction into the CAHS as a Fellow is considered one of the highest honours within Canada’s academic community. CAHS Fellows, […]

Treventis was well represented at the Alzheimer Association International Conference, running from Jul 22-26, 2018, in Chicago, Illinois. In attendance were CEO Christopher Barden; CSO Mark Reed; Chief Medical Officer Dr. Donald Weaver, and Treventis Diagnostics head Dr. Sultan Darvesh. Dr. Weaver presented a poster entitled “Optimization of a Murine CNS IDO1 Pharmacokinetic-Pharmacodynamic Model Using […]

The Treventis diagnostics program, headed by neurologist and medicinal chemist Dr. Sultan Darvesh, was recently featured in two news articles: http://www.nshealth.ca/news/creating-worlds-first-definitive-diagnostic-test-alzheimers-disease https://www.dal.ca/news/2018/01/10/sultan-darvesh–revolutionary-researcher.html?utm_source=Today@Dal&utm_medium=email&utm_campaign=dalnews

Paris (France) and Toronto (Canada), 4 January 2018 – Servier and Treventis announce strategic research partnership in targeting misfolded proteins implicated in neurodegenerative diseases. The collaboration covers a large drug discovery program targeting both tau and amyloïde-β (Aβ), two key proteins involved in Alzheimer’s disease. This therapeutic strategy aims to provide patients with a drug […]